Loading
Life sciences · Journal article
npj Precision Oncology · October 10, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Epithelial–mesenchymal transition (EMT) drives immunotherapy resistance in lung cancer through three interconnected axes: antigen/checkpoint dysregulation, chemokine remodeling, and metabolic reprogramming. We highlight partial EMT (pEMT) as a clinically prevalent hybrid state and biomarker candidate, and metabolic rewiring as an actionable immunometabolic vulnerability. EMT signatures may complement programmed death receptor ligand-1 (PD‑L1), but require treatment-by-biomarker interaction testing. Integrating these axes enables resistance-subtype stratification and precision combination therapy.